Botulinum toxin in pain treatment;Toxina botulínica no tratamento da dor

Revista Brasileira de Anestesiologia

Volumn 59, Issue 3, 2009, Pages 366-381

  Colhado, Orlando Carlos Gomes ^a,b,c,e   Boeing, Marcelo ^d   Ortega, Luciano Bornia ^d  

^a UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

^c Hospital Universitário da UEM   (Brazil)

^d Santa Casa de Maringá   (Brazil)

^e NONE   (Brazil)

Author keywords

Drugs: Botulinum toxin type A; Pain, chronic

Indexed keywords

ACETYLCHOLINE; ANALGESIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; LIDOCAINE; MYOBLOCK; PLACEBO; UNCLASSIFIED DRUG;

CERVICAL DYSTONIA; CERVICAL PAIN; CHOLINERGIC SYNAPSE; CHRONIC PAIN; CLOSTRIDIUM BOTULINUM; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FERMENTATION; HEADACHE; HUMAN; IMMUNOGENICITY; LOW BACK PAIN; MEDICAL LITERATURE; MIGRAINE; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYOFASCIAL PAIN; NERVE CONDUCTION; NERVE ENDING; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; REVIEW; STRABISMUS; TENSION HEADACHE; VISUAL DISORDER; XEROSTOMIA;

EID: 67249116565     PISSN: 00347094     EISSN: 1806907X     Source Type: Journal    
DOI: 10.1590/S0034-70942009000300013     Document Type: Review

References (34)

1. Dressler D, Saberi FA, Barbosa ER - Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005;63:180-185.
2. Lang A - History and uses of BOTOX (botulinum toxin type A). Lippincott's Case Manag 2004;9:109-112.
3. Wenzel RG - Pharmacology of botulinum neurotoxin serotype A. Am J Heath-Syst Pharm 2004;61(suppl 6):s5-10.
4. Setler PE - Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002;18(6 suppl):s119-124.
5. Aguilar-Rebolledo F, Hernandez-Sanchez J, Rayo-Mares D et al. - Toxina botulínica como tratamiento de la espasticidad y distonia en la parálisis cerebral infantil. Gac Méd Mex 2001;137:403-411. (Pubitemid 32916652)
6. Wohlfarth K, Kampe K, Bigalke H - Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 2004;19:s65-67. (Pubitemid 38967514)
7. Unno Ek, Sakato RK, Issy AM - Estudo comparativo entre toxina botulínica e bupivacaína para infiltração de pontos-gatilho em síndrome dolorosa miofascial crônica. Rev Bras Anestesiol 2005;55:250-255.
8. Purves D, Augustine GJ, Fitzpatrick D et al. - Neuroscience. 3 Ed. Massachusetts, Sinauer 2004;110-116.
9. Aoki KR - Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793. (Pubitemid 41427518)
10. Freund B; Schwartz M - Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 2003;4:159-165. (Pubitemid 36523435)
11. Aoki KR - Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248(suppl 1):3-10.
12. Dressler D, Chaná Cuevas P - La toxina botulínica tipo B: Dónde estamos? Rev Chil Neuro-psiquiatr 2002;40:6-8.
13. Mejia NI, Vuong KD, Jankovic J - Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 2005;20:592-597.
14. Cardoso F - Toxina botulínica tipo B no manejo de distonia nãoresponsiva à toxina botulínica tipo A. Arq Neuropsiquiatr 2003;61:607-610.
15. Yablon S - Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders. Neurology 2005;64:1153.
16. Comella CL - Interim results of an observation study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology 2004;62:6141.
17. Graboski CL, Gray DS, Burnham RS - Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005;118:170-175. (Pubitemid 41566596)
18. Sycha T, Samal D, Chizh B et al. - A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006;102:509-516. (Pubitemid 43152605)
19. Sheeran G - Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002;6:460-469.
20. Göbel H, Heinze A, Heinze-Kuhn K et al. - Botulinun toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195-199. (Pubitemid 32241138)
21. Lew MF - Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002;18(6 suppl):s142-146.
22. Porta M - A comparative trial of botulinum toxin type A and methilprednisolone for the treatment of myofascial pain syndrome and pain for chronic muscle spasm. Pain 2000; 85:101-105. (Pubitemid 30110749)
23. Klein AW - The therapeutic potential of botulinum toxin. Dermatol Surg 2004;30:452-455. (Pubitemid 38524173)
24. Porta M, Perreti A, Gamba M et al. - The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 1998;8:346-352 (Pubitemid 28554715)
25. Kamanli A, Kaya A, Ardicoglu O et al. - Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-611. (Pubitemid 41414058)
26. von Lindern JJ, Niederhagen B, Bergé S et al. - Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003;61:774-778 (Pubitemid 36754028)
27. Jabbari B, Ney J, Sichani A et al. -Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med 2006;7:260-264. (Pubitemid 43676672)
28. Gassner HG, Sherris DA - Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc 2000;75:701-704 (Pubitemid 30441499)
29. Silberstein SD, Gobel H, Jensen R et al. - Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006;26:790-800 (Pubitemid 43882987)
30. Smuts JA, Schultz D, Barnard A - Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44: 801-805. (Pubitemid 39310965)
31. Allen G, Galer BS, Schwartz L - Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. Pain 1999;80:539-544 (Pubitemid 29182703)
32. Argoff CE - Botulinum toxin type A treatment of myofascial pain with CRPS type I (reflex sympathetic dystrophy): a pilot study, em: World Pain Congress (IASP), Vienna, Austria, august 1999 - Poster presentation.
33. Jabbari B, Maher N - Effectiveness of botulinum toxin A against the segmental burning pain of spinal cord origin. In: International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, 8-12, 2002 - Poster presentation.
34. Lang AM - Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003;(3/suppl 1)84:s69-73.